ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2034

Nontuberculous Mycobacterial Diseases Do Not Cause Positive Autoantibody Testing, Results from a Tertiary Pulmonary Care Center

Barbara Goldstein1, Jeffery J. Swigris2, Shannon Kasperbauer1, Pearlanne Zelarney1 and JoAnn Zell1, 1Medicine, National Jewish Health, Denver, CO, 2National Jewish Health, Denver, CO

Meeting: 2015 ACR/ARHP Annual Meeting

Date of first publication: September 29, 2015

Keywords: autoantibodies, Infection, laboratory tests and tuberculosis

  • Tweet
  • Email
  • Print
Session Information

Date: Monday, November 9, 2015

Title: Infection-related Rheumatic Disease

Session Type: ACR Concurrent Abstract Session

Session Time: 2:30PM-4:00PM

Background/Purpose:
National Jewish Health (NJH) is a tertiary referral center for pulmonary and
immunologic disease.  The infectious disease division at NJH specializes in the
care of patients with chronic pulmonary infections, especially those with nontuberculous
mycobacterial disease (NTM). The NTM patients have bronchiectasis and their
sera are sent for autoantibodies to determine if there may be an underlying
concomitant rheumatic disease predisposing to infection.  It is well known that
chronic infectious disease may increase the false positive rate of some
immunologic tests.  An example is a rheumatoid factor found in tuberculosis
and/or hepatitis C.  We chose to retrospectively analyze patients with NTM and
autoantibodies to determine if these laboratory tests were more frequently
positive in the absence of defined rheumatologic illness.

Methods:  We
queried our electronic medical record from February 2008 through May of 2015. 
We defined NTM cases as those with positive cultures at our institution or an
appropriate ICD-9 code within the medical record.   Patients with defined
autoimmune disease (ICD- 9 codes with 710 or 714) and tuberculosis were
excluded from our entire analysis.  Antinuclear antibody (ANA), rheumatoid
factor (RF), cyclic citrullinated peptide (CCP), SSA and SSB results were
tabulated.  We used a Chi-squared analysis to determine if these autoantibodies
were more likely to return as positive in the NTM patients when compared with
our overall patient population. 

Results: During
the study period, 3,721 cases of NTM were seen at NJH and 65% had at least one
autoantibody resulted. RF, CCP and ANA testing were not more likely to return
as positive in the setting of NTM. Furthermore, non-NTM cases within NJH were
more likely to have a positive SSA or SSB antibody (OR 0.53, χ2
19.1 with 1DF, p 0.0001 or OR 0.41, χ2 10.0 with IDF, p 0.0015
see Table 1).

Conclusion:  Patients
with NTM were not more likely to have a positive ANA, RF, CCP as compared to
the overall population. Additionally, the SSA and SSB were less likely to be
positive in patients with NTM. This may indicate that NTM does not cause false
positive results as is seen in diseases like tuberculosis.  Therefore, in this
setting, positive autoantibodies could indicate the presence of occult
autoimmune disease. 

Autoantibody

NTM+

NTM-

 

RF+

822

3747

OR 1.01

χ2 0.04 with 1DF

p 0.84

RF-

1297

5971

 

CCP+

38

593

OR 1.32

χ2 0.025 with 1DF

p 0.12

CCP-

369

7576

 

ANA+

702

4478

OR 1.00

χ2 0.004 with 1DF

p 0.95

ANA-

1510

9602

 

SSA+

54

346

OR 0.53

χ2 19.1 with 1DF

p 0.0001

SSA-

2001

6767

 

SSB+

13

109

OR 0.41

χ2 10.0 with 1DF

p 0.0015

SSB-

2040

6934

 

Figure 1: 2 x 2 contingency tables representing
individual patients and autoantibody results (excluding patients with defined
autoimmune disease), odds ratios (OR), Chi-squared test ( χ2),
and p values

 


Disclosure: B. Goldstein, None; J. J. Swigris, None; S. Kasperbauer, None; P. Zelarney, None; J. Zell, None.

To cite this abstract in AMA style:

Goldstein B, Swigris JJ, Kasperbauer S, Zelarney P, Zell J. Nontuberculous Mycobacterial Diseases Do Not Cause Positive Autoantibody Testing, Results from a Tertiary Pulmonary Care Center [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/nontuberculous-mycobacterial-diseases-do-not-cause-positive-autoantibody-testing-results-from-a-tertiary-pulmonary-care-center/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2015 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/nontuberculous-mycobacterial-diseases-do-not-cause-positive-autoantibody-testing-results-from-a-tertiary-pulmonary-care-center/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology